Revolutionising Healthcare for Rare Diseases: South Africa’s Pioneering Biobank Leads the Way

Revolutionising Healthcare for Rare Diseases: South Africa’s Pioneering Biobank Leads the Way

advanced divider

The North-West University’s Centre for Human Metabolomics (CHM) hosting the National Metabolomics Platform (NMP) established the first-ever Biobank dedicated to rare diseases on the African continent in 2019. This transformative initiative is revolutionising healthcare for rare diseases, with far-reaching implications for patients and researchers worldwide.

Understanding the Significance of a Biobank

Before diving into the ground-breaking work of the Biobank, it’s essential to grasp the concept’s significance. Think of a Biobank as a specialised repository, akin to a vast library, but instead of books, it stores precious biological samples sourced from donors. These samples, including blood, tissue, and DNA, serve as vital pieces of the puzzle that scientists use to investigate the complexities of the human body and the underlying causes of diseases. In the context of rare diseases, this Biobank acts as a unique section within the library, focusing exclusively on collecting samples from individuals afflicted with these uncommon and poorly understood conditions.

The Birth of South Africa’s First Rare Disease Biobank

The Biobank came into existence as a response to a critical need identified at the Potchefstroom Laboratory for Inborn Errors of Metabolism (PLIEM). Established in 1983, PLIEM has been at the forefront of diagnosing Inborn Errors of Metabolism (IEM), a category of rare genetic disorders that hinder the body’s ability to convert food into energy. These disorders are primarily caused by defects in specific proteins (enzymes) critical for metabolic processes. Recognising the scarcity of resources for studying these rare diseases, the Biobank was conceived to collect and store samples that would aid future research. Many of these diseases are exceedingly rare, making sample collection a protracted process. To address this, participants in the Biobank are asked to grant broad consent, allowing their samples and data to be used for various future medical research on these rare birth defects, always under the oversight of the NWU-HREC, ensuring protection for the donors and their families.

The Mission and Vision of the CHM Biobank

The Biobank’s mission is clear: to provide high-quality analytical, research, and consultancy services that enhance the understanding of congenital anomalies (rare birth defects). Moreover, it’s committed to safeguarding personal information, promoting transparency, communication, respect, and accountability in all research studies using its resources. The vision of the CHM Biobank is to become not only the first rare inborn disease biobank in South Africa and Africa but also a global leader in rare disease research. It aims to cultivate strong relationships with all participants, obtain ISO 20387 accreditation, and become a hub for biobank operational training in South Africa and the African continent.

Contributing to Global Research on Rare Diseases

The significance of the CHM Biobank extends far beyond South Africa’s borders. Rare diseases remain under-researched on a global scale, making the study of these conditions an opportunity for networks like DIPLOMICS (Distributed Platform for ‘Omics’) to conduct comprehensive research. The genetic diversity of South Africa’s population adds substantial value to the Biobank, making it an attractive resource for international researchers. Through collaborations and partnerships with organisations like Rare Disease South Africa (RDSA), Sanofi Genzyme, Takeda, FYMCA Medical, and even Newcastle University in the UK, theBiobank is poised to play a pivotal role in advancing rare disease research in South Africa and the wider global community.

Empowering Patients and Shaping the Future

Patients living with rare diseases stand to gain significantly from the Biobank. By participating in this network, they become a part of a broader effort to better understand these conditions, potentially leading to the development of life-changing treatments. Collaborations with patient advocacy groups like RDSA ensure that participants receive not only the benefits of research but also support structures that come with it. This partnership also allows the dissemination of information on new developments in treatments and clinical trials.

A Multitude of Services for Researchers and Medical Professionals

The Biobank offers an array of services to researchers and medical professionals, including sample storage and management, research collaboration opportunities, data sharing and analysis, ethical and legal guidance, educational outreach, and support for research project design and management. This comprehensive support infrastructure is essential for catalysing innovative research on rare diseases.

A Promising Future for Rare Disease Research

Looking ahead, as collaborations and expertise develop, the range of services and capabilities is likely to expand, further enhancing its contributions to rare disease research. Remarkably, considering its humble beginning with just three samples in 2019, the Biobank now boasts acollection of samples from 460 participants, with plans to rapidly expand.

Shaping the Landscape of Healthcare and Research

According to Dr. Elne Conradie (Ph.D, Pr.Sci.Nat), ISBER Director-at-large for Europe, Middle East, and Africa, and Senior Subject Specialist in Biobank and Quality Management at the NMP, “In the larger context, the Biobank, alongside rare disease research in South Africa, holds immense promise. It could drastically change the healthcare and medical research landscapes in terms of leading to better diagnosis and treatment, providing diverse genetic insights due to SA’s varied population groups, fostering global collaboration, driving research innovation, empowering rare disease patients and their families, attracting investment and talent, offering educational opportunities, advancing rare disease advocacy and policy development, creating translational research opportunities, and upholding the highest standards of data privacy and ethics.”

Join Us in Our Mission for Rare Disease Advancements

Whether you’re a scientist, healthcare professional, or someone directly affected by rare diseases, your involvement can make a significant impact!

Contact us today to become a vital part of this mission to advance our understanding of rare diseases.

GCxGC-TOFMS Untargeted

Compound list

Spectra identified via comparison with library spectra

NMR Untargeted

Compound list

Spectra identified via comparison with library spectra

LDL Cholesterol Subfractions

Compound list

The LDL subfraction test measures up to twelve lipoprotein fractions and subfractions (VLDL, mid-bands A-C and LDL 1 through 7)

HDL Cholesterol Subfractions

Compound list

Separates and quantifies up to 10 HDL subfractions, classified from large buoyant HDL lipoproteins (HDL-L) to small-dense HDL lipoproteins (HDL-S).